Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

827
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
827
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

668
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
668
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.1K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.1K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.3K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.3K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.4K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing.

Nature communications·2026
Same author

HIV Status Disclosure Among Perinatally Infected Adolescents Living With HIV (ALHIV): Perspectives of Primary Caregivers, Healthcare Providers, and ALHIV in Mumbai, India.

Cureus·2026
Same author

Responding Appropriately to Safety Signals in Infants Exposed to the 6-month BDLLfx/BDLCfz Regimen In Utero.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

The looming crisis of bedaquiline-resistant tuberculosis and a promising way forward.

The Lancet. Infectious diseases·2026
Same author

Implementation of tuberculosis care cascade among adult people living with HIV registered in anti-retroviral therapy centres in Odisha, India, 2020-2023.

BMC infectious diseases·2026
Same author

Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Mar 28, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K

Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?

Stella Benbaba1, Petros Isaakidis1,2, Mrinalini Das1

  • 1Médecins Sans Frontières, Mumbai, India.

Plos One
|December 30, 2015
PubMed
Summary

Directly-observed therapy (DOT) for drug-resistant tuberculosis (DR-TB) was not followed by most patients in Mumbai, as reported by patients and providers. This suggests patient-centered adherence strategies may be more effective for DR-TB treatment.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format
12:39

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Published on: June 24, 2011

39.0K

Related Experiment Videos

Last Updated: Mar 28, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format
12:39

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Published on: June 24, 2011

39.0K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Directly-observed therapy (DOT) is recommended for drug-resistant tuberculosis (DR-TB) patients.
  • Limited evidence exists on the field implementation of direct observation (DO) for DR-TB.
  • This study investigated DO adherence in a Médecins Sans Frontières (MSF) DR-TB program in Mumbai, India.

Purpose of the Study:

  • To assess the implementation and adherence to directly-observed therapy (DOT) among drug-resistant tuberculosis (DR-TB) patients.
  • To identify reasons for non-adherence to DOT in a high-burden setting.
  • To evaluate the effectiveness of DOT as a treatment strategy for DR-TB.

Main Methods:

  • A cross-sectional, mixed-methods study involving 70 DR-TB patients, 65 DOT-providers, and 21 MSF health staff.
  • Quantitative data collected via questionnaires on DOT adherence ('Strict DO' and 'following DO').
  • Qualitative data from interviews with patients, DOT-providers, and family members to explore implementation challenges.

Main Results:

  • Only 14% of patients self-reported 'Strict DO' and 20% 'following DO'.
  • DOT-providers reported 46% adherence, while MSF staff reported none.
  • Key reasons for non-adherence included DOT-provider unavailability, time constraints, stigma, and adverse treatment events.

Conclusions:

  • A majority of DR-TB patients in Mumbai did not adhere to DOT, a finding corroborated by both patients and care-providers.
  • These results may reflect challenges in DOT implementation in many high-burden settings.
  • Patient-centered adherence strategies may offer a more effective approach for supporting DR-TB treatment.